BG100517A - Комбинация от бисфосфонати и стимулатори на секрецията на соматотропния хормон - Google Patents

Комбинация от бисфосфонати и стимулатори на секрецията на соматотропния хормон

Info

Publication number
BG100517A
BG100517A BG100517A BG10051796A BG100517A BG 100517 A BG100517 A BG 100517A BG 100517 A BG100517 A BG 100517A BG 10051796 A BG10051796 A BG 10051796A BG 100517 A BG100517 A BG 100517A
Authority
BG
Bulgaria
Prior art keywords
bisphosphonates
combination
growth hormone
hormone secretagogues
secretagogues
Prior art date
Application number
BG100517A
Other languages
English (en)
Inventor
Barry Gertz
Gideon Rodan
Roy Smith
Matthew Wyvratt
Arthur Patchett
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of BG100517A publication Critical patent/BG100517A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретението се отнася до бисфосфонати в комбинация със стимулатори на секрецията на соматотропнияхормон, чрез които се намаляват вредните последици от остеопорозата у възрастни пациенти.
BG100517A 1993-10-19 1996-04-18 Комбинация от бисфосфонати и стимулатори на секрецията на соматотропния хормон BG100517A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13929693A 1993-10-19 1993-10-19
US25909194A 1994-06-13 1994-06-13
PCT/US1994/011912 WO1995011029A1 (en) 1993-10-19 1994-10-18 Combination of bisphosphonates and growth hormone secretagogues

Publications (1)

Publication Number Publication Date
BG100517A true BG100517A (bg) 1996-11-29

Family

ID=26837073

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100517A BG100517A (bg) 1993-10-19 1996-04-18 Комбинация от бисфосфонати и стимулатори на секрецията на соматотропния хормон

Country Status (16)

Country Link
EP (1) EP0813414A4 (bg)
JP (1) JPH09504525A (bg)
KR (1) KR960705575A (bg)
CN (1) CN1136278A (bg)
AU (1) AU8083694A (bg)
BG (1) BG100517A (bg)
BR (1) BR9407869A (bg)
CA (1) CA2173333A1 (bg)
CZ (1) CZ109196A3 (bg)
FI (1) FI961681A (bg)
HU (1) HUT75224A (bg)
LV (1) LV11432B (bg)
NO (1) NO961536L (bg)
PL (1) PL314003A1 (bg)
SK (1) SK49796A3 (bg)
WO (1) WO1995011029A1 (bg)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
EP0828754B1 (en) * 1995-05-29 2005-02-02 Pfizer Inc. Dipeptides which promote release of growth hormone
AU7522896A (en) * 1995-10-27 1997-05-15 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
ES2268713T3 (es) 1995-12-13 2007-03-16 MERCK & CO., INC. Ensayos de receptores de secretagogos de la hormona de crecimiento.
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL126983A0 (en) * 1996-05-31 1999-09-22 Novo Nordisk As Growth hormone components and bone anti-resorptive agent in cyclic (coherence) treatment of osteoporosis
AU4993497A (en) * 1996-10-25 1998-05-22 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
IT1296495B1 (it) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
CA2333857A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
EP1112282A4 (en) 1998-08-10 2002-10-31 Merck & Co Inc RECEPTOR OF THE GROWTH HORMONE SECRETION PROMOTER FROM THE DOG
EP1112071A4 (en) * 1998-08-18 2003-03-19 Lilly Co Eli SECRETAGOGUES OF GROWTH HORMONES
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
WO2000074685A1 (fr) * 1999-06-02 2000-12-14 Sumitomo Pharmaceuticals Co., Ltd. Preparations orales d'etidronate disodique
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
US6548042B2 (en) 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
DK1372669T3 (da) 2001-01-23 2005-10-17 Gador Sa Bisphosphonatholding sammensætning til forebyggelse og/eller behandling af metaboliske knoglesygdomme, fremgangsmåde til fremstilling af sådanne sammensætninger og anvendelse deraf
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
WO2003087070A2 (en) 2002-04-09 2003-10-23 Eli Lilly And Company Growth hormone secretagogues
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
DK1622630T3 (da) * 2003-05-07 2012-12-17 Osteologix As P009368epdk1
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
EP2364705A3 (en) 2004-08-19 2012-04-04 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
MX2007006382A (es) 2004-11-29 2007-07-11 Vertex Pharma Moduladores de receptores muscarinicos.
US7858635B2 (en) 2005-12-22 2010-12-28 Vertex Pharmaceuticals Incorporated Spiro compounds as modulators of muscarinic receptors
WO2007100670A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Spiro condensed piperidnes as modulators of muscarinic receptors
AU2007221214A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
US7858790B2 (en) 2006-06-29 2010-12-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7696201B2 (en) 2006-08-15 2010-04-13 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2007284350A1 (en) 2006-08-18 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
US20100099640A1 (en) 2007-05-04 2010-04-22 Joannes Geuns Tissue degeneration protection
WO2009045519A1 (en) 2007-10-03 2009-04-09 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
US11981909B2 (en) 2018-06-06 2024-05-14 Massachusetts Institute Of Technology Circular RNA for translation in eukaryotic cells
SG11202112922WA (en) 2019-05-22 2021-12-30 Massachusetts Inst Technology Circular rna compositions and methods
EP3920976B1 (en) 2019-12-04 2023-07-19 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU569391B2 (en) * 1984-04-30 1988-01-28 Procter & Gamble Company, The Treating osteoporosis
AU568433B2 (en) * 1984-04-30 1987-12-24 Procter & Gamble Company, The Treating osteoporosis
CZ151495A3 (en) * 1992-12-11 1995-12-13 Merck & Co Inc Spiropiperidine derivatives, process of their preparation and a pharmaceutical composition containing thereof
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) * 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5545735A (en) * 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone

Also Published As

Publication number Publication date
JPH09504525A (ja) 1997-05-06
LV11432A (lv) 1996-08-20
WO1995011029A1 (en) 1995-04-27
EP0813414A1 (en) 1997-12-29
NO961536L (no) 1996-06-18
CN1136278A (zh) 1996-11-20
CA2173333A1 (en) 1995-04-27
HUT75224A (en) 1997-04-28
AU8083694A (en) 1995-05-08
FI961681A0 (fi) 1996-04-17
BR9407869A (pt) 1996-10-29
LV11432B (en) 1996-12-20
KR960705575A (ko) 1996-11-08
NO961536D0 (no) 1996-04-18
EP0813414A4 (en) 1999-07-21
PL314003A1 (en) 1996-08-05
CZ109196A3 (en) 1996-10-16
HU9601013D0 (en) 1996-06-28
SK49796A3 (en) 1997-05-07
FI961681A (fi) 1996-06-12

Similar Documents

Publication Publication Date Title
BG100517A (bg) Комбинация от бисфосфонати и стимулатори на секрецията на соматотропния хормон
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
DE3484933D1 (de) Implantat zur befestigung von zahnprothesen.
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
EP0680525A1 (en) FIBERS.
NO167122C (no) Implanterbar kneprotese.
BG100960A (bg) Дозирани форми с контролирано освобождаване на азитромицин
UA43378C2 (uk) Композиція для лікування респіраторного дистрес-синдрому новонароджених та респіраторного дистрес-синдрому дорослих
ZA841597B (en) Human nerve growth factor by recombinant technology
DE3466879D1 (en) Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
DE3775371D1 (de) Schenkelhalsprothese.
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
EP0610286A4 (en) Recombinant immunotoxins.
MX9701187A (es) Nuevas lactamas naftofusionadas n-substituidas.
HK1053264A1 (en) Phosphonate analogues of mannose-6-phosphate and their use in the treatment of wounds and fibrotic disorders.
AU553269B2 (en) 2,3-diaryl-5-halo thiophenes
ES8707488A1 (es) Un metodo para preparar maleato de 2-terc-butilamino-3'-cloropropiofenona
AU5732190A (en) Glycoprotein hormone receptor molecules
ZA878182B (en) Enhancement of prazosin
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
EP1056458A4 (en) METHODS FOR TREATING PAIN, INCLUDING CHRONIC AND WOMAN-SPECIFIC PAIN
DE3485580D1 (de) Algorithmus zur verabreichung von insulin.
GR3001850T3 (en) Expellants of phytopathogenic microbes